76 related articles for article (PubMed ID: 9467283)
21. [2008 National Cardiology Guidelines: Prioritization requires consideration to other factors than scientific studies alone].
Eklund K; Grip L; Israelsson B; Levin LA; Lindahl B; Wallentin L
Lakartidningen; 2008 May 7-13; 105(19):1408-9; discussion 1409. PubMed ID: 18574983
[No Abstract] [Full Text] [Related]
22. [Economic analysis of secondary prevention of coronary heart disease with simvastatin (Zocor) in Germany].
Obermann K; Mattias Graf ; Schulenburg JM; Mautner GC
Med Klin (Munich); 1997 Nov; 92(11):686-94. PubMed ID: 9480401
[TBL] [Abstract][Full Text] [Related]
23. [Heart Protection Study].
Larsen ML; Hildebrandt PR
Ugeskr Laeger; 2002 Jan; 164(3):348. PubMed ID: 11816337
[No Abstract] [Full Text] [Related]
24. Assessment of the impact of fibrates and diet on survival and their cost-effectiveness: evidence from randomized, controlled trials in coronary heart disease and health economic evaluations.
Montagne O; Vedel I; Durand-Zaleski I
Clin Ther; 1999 Nov; 21(11):2027-35. PubMed ID: 10890271
[TBL] [Abstract][Full Text] [Related]
25. [Cost-effectiveness analysis of cardiovascular disease prevention: a graded list as aid to the rational distribution of resources].
Lindholm L; Hallgren CG; Boman K; Markgren K; Weinehall L; Ogren JE
Lakartidningen; 1999 Jun; 96(23):2858-63, 2865-6. PubMed ID: 10405534
[TBL] [Abstract][Full Text] [Related]
26. [Consequences of cholesterol reduction in cardiovascular diseases. What costs should be allowed to prolong life a year?].
De Faire U
Lakartidningen; 1997 Dec; 94(49):4607-9. PubMed ID: 9445932
[No Abstract] [Full Text] [Related]
27. RE: M Thomas. The change of cost: reference-based pricing and the statins. 1999;15:535-8.
McNee W
Can J Cardiol; 1999 Nov; 15(11):1287. PubMed ID: 10841625
[No Abstract] [Full Text] [Related]
28. Enhanced hype.
Harrison DG; Brown WV; Raggi P
Am J Cardiol; 2008 Aug; 102(3):368-9. PubMed ID: 18638604
[TBL] [Abstract][Full Text] [Related]
29. [For coronary disease patients is certain: the lower the LDL the better].
MMW Fortschr Med; 2006 Jun; 148(24):6. PubMed ID: 16850797
[No Abstract] [Full Text] [Related]
30. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
[TBL] [Abstract][Full Text] [Related]
31. Cholesterol-lowering drug improves survival after heart transplant.
FDA Consum; 2003; 37(1):7-8. PubMed ID: 12625296
[No Abstract] [Full Text] [Related]
32. [Basic principles of cost-benefit analysis in long-term treatment of risk factors].
Szucs TD; Gutzwiller F
Schweiz Med Wochenschr; 1998 Dec; 128(49):1958-64. PubMed ID: 9887476
[TBL] [Abstract][Full Text] [Related]
33. Money, money, money.
Drug Ther Bull; 2010 Jul; 48(7):73. PubMed ID: 20631194
[No Abstract] [Full Text] [Related]
34. The change of cost: reference-based pricing and the statins.
Thomas M
Can J Cardiol; 1999 May; 15(5):535-8. PubMed ID: 10350662
[No Abstract] [Full Text] [Related]
35. [Clinicohemadynamic and biochemical the effect of patients with coronary heart disease use combinated lactoovovegetarian diets and simvastatin].
Medkova IL; Ivanov AN; Mosiakina LI; Biriukova LS
Vopr Pitan; 2006; 75(5):49-52. PubMed ID: 17172171
[TBL] [Abstract][Full Text] [Related]
36. A clinical focus on statins.
Auer J; Eber B
Curr Opin Investig Drugs; 2001 Mar; 2(3):382-8. PubMed ID: 11575709
[TBL] [Abstract][Full Text] [Related]
37. A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.
Maclaine GD; Patel H
Int J Clin Pract; 2001 May; 55(4):243-9. PubMed ID: 11406909
[TBL] [Abstract][Full Text] [Related]
38. PHARMAC and statins.
Bennett W; McNee W
N Z Med J; 1998 Nov; 111(1077):439-40. PubMed ID: 9861928
[No Abstract] [Full Text] [Related]
39. [Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?].
Sudhop T; von Bergmann K
MMW Fortschr Med; 2003 May; 145(21):19. PubMed ID: 12845862
[No Abstract] [Full Text] [Related]
40. [Ezetimib plus statin combination. A strong duo].
MMW Fortschr Med; 2002 Nov; 144(48):53. PubMed ID: 12532547
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
